


6<sup>th</sup> International Workshop on PET in Lymphoma Palais de l'Europe. Menton, France September 20 -21, 2016


## Peripheral T-Cell lymphoma: Old and new prognostic factors.



Pr. Andrea Gallamini Département de recherche et innovation médicale Hopital A. Lacassagne. Nice (France).

## PTCL: subtype frequencies





International T-cell project. J Clin Oncol 2008; 26:4124-4130.

# Expert Agreement (morphology and IHC) with Consensus Diagnosis

Histotype	Consensus	Histotype	Consensus		
ALCL, ALK+	91%	PTCL, unspecified	74%		
ATLL	93%	Panniculitis-like	75%		
Nasal NK/T-cell	84%	ALCL, ALK-	74%		
Angioimmunoblastic	81%	Hepatosplenic	72%		
Enteropathy-type	79%	Cutaneous ALCL	66%		

Int. T- Cell Project Vose JM et al. J Clin Oncol 26:4124-4130, 2008

# **Plenary Paper**

#### LYMPHOID NEOPLASIA


## Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma

Javeed Iqbal,<sup>1</sup> George Wright,<sup>2</sup> Chao Wang,<sup>1</sup> Andreas Rosenwald,<sup>3</sup> Randy D. Gascoyne,<sup>4</sup> Dennis D. Weisenburger,<sup>5</sup> Timothy C. Greiner,<sup>1</sup> Lynette Smith,<sup>6</sup> Shuangping Guo,<sup>1</sup> Ryan A. Wilcox,<sup>7</sup> Bin Tean Teh,<sup>8</sup> Soon Thye Lim,<sup>8</sup> Soon Yong Tan,<sup>8</sup> Lisa M. Rimsza,<sup>9</sup> Elaine S. Jaffe,<sup>10</sup> Elias Campo,<sup>11</sup> Antonio Martinez,<sup>11</sup> Jan Delabie,<sup>12</sup> Rita M. Braziel,<sup>13</sup> James R. Cook,<sup>14</sup> Raymond R. Tubbs,<sup>14</sup> German Ott,<sup>15</sup> Eva Geissinger,<sup>3</sup> Philippe Gaulard,<sup>16</sup> Pier Paolo Piccaluga,<sup>17</sup> Stefano A. Pileri,<sup>17</sup> Wing Y. Au,<sup>18</sup> Shigeo Nakamura,<sup>19</sup> Masao Seto,<sup>19</sup> Francoise Berger,<sup>20</sup> Laurence de Leval,<sup>21</sup> Joseph M. Connors,<sup>4</sup> James Armitage,<sup>22</sup> Julie Vose,<sup>22</sup> Wing C. Chan,<sup>6</sup> and Louis M. Staudt,<sup>2</sup> for the Lymphoma Leukemia Molecular Profiling Project and the International Peripheral T-cell Lymphoma Project

From www.bloodjournal.org by guest on October 8, 2015.


The Lymphoma Leukemia Molecular Profiling Project (LLMPP), (University of Nebraska, Singapore, Bologna, Paris-Creteil, Lausanne) The International Peripheral T-cell Lymphoma Project (IPTCL) University of Nebraska (UNMC) National Cancer Institute/National Institute of Health (NCI/NIH)

## Overall survival by morphological diagnosis (N= 372)




-ALK(+)ALCL patients shows better clinical outcome, whereas ATLL patients show significantly poor overall survival.

### Morphological and molecular diagnosis (N= 372)



-Of 152 PTCL-NOS, 56 cases (37%) were classified into



- Of 117 AITL, 26 cases (22%) were changed to PTCL-NOS.

## Clinical prognostic models in PTCL


- •The number of prognosticators (single or included in models) is inversely related to disease curability
- •In PTCL, at least seven different prognostic models have been proposed so far.

IPI (International Prognostic Index):	NHL	Shipp 1993
PIT (Prognostic model for PTCL)	PTCL-U	Gallamini 2004
IPTCLP (International PTCL Project)	PTCL	Vose 2005
mPIT (Modified PIT)	PTCL-U	Went 2006
AIP (Angioimmunoblastic TCL Prognostic Index)	AITL	Tokunaga 2012
KPI Korean Prognostic Index for NK/T cell "nasal-type" lymphoma	NKTCL	Lee 2006
B <sub>2</sub> M-Age model for ALCL	ALCL	Sibon 2012

NCCN National Comprehensive Cancer Network ®

#### NCCN Guidelines<sup>™</sup> Version 3.2016 Peripheral T cell Lymphoma

NCCN Guidelines Index NHL Table of Contents Discussion




<sup>a</sup>Adapted with permission, The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-hodgkin's lymphoma N Engl J Med 329:987-994, 1993. Copyright © 1993 Massachusetts Medical Society. All rights reserved.

<sup>b</sup>Gallamini A, Stelitano C, Calvi R, et al.: Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective muticentric clinical study. Blood 2004; 103: 2474 - 2479



Horwitz SM: J Natl Compr Canc Netw. 2016 Sep;14(9):1067-79.


PTCL: clinical usefulness of prognostic models



Vose et al. ASH 2005; abstr 811; Gutierrez-Garcia Ann Oncol 2011; 22, 397-204 IPI, International prognostic index; FFS, failure-free survival; OS, overall survival

# Prospective prognostic models


## T-cell Project: subtypes by geographic area (N=1391 validated on 30/04/2016)




# The role of functional imaging in PTCL

	Prognostic factors	Predictive factors				
PROS	Available at baseline for all patients	Include both known and unknown factors				
PRUS	Allow comparison between groups	Accurate				
CONS	Unspecific	Available only during treatment				
CONS	Retrospectively arisen	Treatment-restricted				

## Interim PET in PTCL (N=63)



## Outcome according to MTV



- Median TMTV0 = 224 cm<sup>3</sup> (5-3824 cm<sup>3</sup>)
- Cut off 230 cm<sup>3</sup> by ROC analysis

#### 2-year PFS :


 $TMTV0 \le 230 \text{ cm}^3 : 71\% \text{ (65-77\%)}$  $TMTV0 > 230 \text{ cm}^3 : 26\% \text{ (20-32\%)}$ 

#### 2-year OS :

 $TMTV0 \le 230 cm^3$ : 80% (75-85%)  $TMTV0 > 230 cm^3$ : 50% (42-58%)

Cottereau AS: Haematol. Oncol. 2015; 33 [abstr. 084].

## The relevance of master gene expression GATA3 and T-bet responsible for T-cell ontogeny



Broere F: in Nijkamp and Parnham eds. Principles of immunopharmacology. 3<sup>rd</sup> ed. Springer 2011

## LETTERS TO THE EDITOR

C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas


		n-PTCL			PTCL-NOS	
	C-MYC			C-MYC		
C-MYC	-	Ki-67	-	-	Ki-67	-
Ki-67	< 0.001	-	GATA3	0.001	-	GATA3
GATA3		0.754	-	0.004	0.111	-

www.impactjournals.com/oncotarget/

**Oncotarget, Advance Publications 2016** 

#### GATA3 expression correlates with poor prognosis and tumorassociated macrophage infiltration in peripheral T cell lymphoma

## GATA3, t-bet and OS in PTCL




Zhang W: Oncotarget. 2016 Aug 29. doi: 10.18632/oncotarget.11673

Angioimmunoblastic T-cell lymphoma (AILT): clinical and molecular prognosticators


## Angioimmunoblastic T-cell lymphoma (AILT)

- Median age of patients > 60 years
- Male predominance
- The primary site of disease are the lymph nodes,
- 80%-90% of patients exhibit advanced and ENS disease
- Polyclonal hyper γ-globulinemia, hemolytic anemia, with positive Coombs test
- Proliferation of T<sup>FH</sup> cells with a CD10+, CXCL-13+, PD-1+ and EBER-ISH+ phenotype.




Group 1: 0-1 factors; group 2: 2 factors; group 3: 3 factors; group 4: 4-6 factors.

## IDH2<sup>R172</sup>/TET2 are specific epigenetic mutations in AILT




- IDH2 <sup>R172</sup>: Epigenetic alteration with aberrant DNA and histone metylation.
- Found in 32.8% of AILT cases and only 1/24 PTCL-NOS
- IDH2<sup>R172</sup>/TET2 mutation enriches the T<sup>FH</sup> phenotype.
- Mutant IDH2 inhibits various histone demethylases.
- In AITL significantly elevated levels of H3K27me3 (metylated histone) are found.

Anaplastic Large-cell Lymphoma (ALCL): clinical, immunohistochemical and molecular prognosticators



Sibon D: J Clin Oncol 2012; 30:3939-3946.

Anaplastic Large-Cell Lymphoma (ALCL)




ALCL Alk+: CD 30+, Alk+, EMA + ALCL Alk-: CD 30+, Alk-, EMA -

5-year FFS, 36% versus 20%, respectively; p=0.012 5-year OS, 49% versus 32%, respectively; p=0.032

Hapgood G: Blood. 2015;126(1):17-25

### ALCL : Immunohistochemistry, cytogenetics and molecular profile



In the future, combining clinical and genetic biomarkers may aid in risk stratification and help guide initial patient management.


Recurrent translocations involving	Recurrent translocations involving
ALK	DUSP22:IRF4
t(2;5)(p23;25) ALK:NPM1 (85%)	(6p25.3) (30%)
t(2;v) (15%)	Recurrent translocations involving TP63 (3q28) 8%
Gains: 7, 17p, 17q	Gains: 1q, 6p, 8q, 12q
Deletions: 4, 11q, 13q	Deletions: 6q, 4q, 13q

Hapgood G: Blood. 2015;126(1):17-25

# CD 30 expression in peripheral T-cell lymphoma


## CD 30 expression in PTCL

% of CD30 <sup>+</sup> tumor cells	$\frac{ALCL \ ALK^+}{(N = 61)}$	$\frac{ALCL ALK^{-}}{(N = 19)}$	$\frac{\text{PTCL NOS}}{(\text{N} = 141)}$	AITL (N = 97)	ENKTL (N = 28)	EATL (N = 14)	$\frac{\text{ATLL}}{(N = 9)}$	HSTL (N = 7
Score 0	0	0	59	36	15	7	4	7
<5%			42%	37%	53.5%	50%	44%	100%
Score 1	0	0	37	46	2	0	1	0
5-24%			26%	47%	7%		11%	
Score 2	3	0	13	10	3	0	3	0
25-49%	5%		9%	10%	11%		33%	
Score 3	1	0	14	5	4	1	1	0
50-75%	2%		10%	5%	14%	7%	11%	
Score 4	57	19	18	0	4	6	0	0
>75%	93%	100%	13%		14%	43%		
Total positive cases (scores 1-4)	61	19	82	61	13	7	5	0
	100%	100%	58%	63%	46%	50%	55.5%	
Strongly positive cases (scores 3-4)	58	19	32	5	8	7	1	0
	95.1%	100%	23%	5%	28.5%	50%	11%	




# Positive (5-75%)Strongly pos.(> 50%)

## Brentuximab Vedotin Effective in Patients With R/R ALCL Response, % (95% CI)



• Reduction in tumor volume was observed in 97% of patients



- Median OS was not reached at the time of the analysis; 18 patients had died
- Median PFS among all patients was 13.3 months by IRF

Pro B, et al. J Clin Oncol. 2012;30(18):2190-2196.

or		ient		Non-ALCL (n=7)	%	100					ent for
ОР	ປ	treatm	nation	-non (n	٢	7	7	0	0	0	cycle 6 ssessme points.
<b>Р СН</b>	Tq +	ination <sup>1</sup>	Combination	ALCL (n=19)	%	100	22	16			itment), ponse as ese time
Wit	D30	combi		al al	۲	19	16	ŝ	0	0	tial trea able res fore the
ially	ne C	ential or	Sequential	ALCL (n=13)	%	85	62	23		15	3 (sequent last avails tment be
ent	nt-li	r sequ	Sequ	Ψ U	-	11	8	e	0	2	t cycle { t), or at ied trea
/edotin Sequ	h CHP in Fro	Best response after sequential or combination treatment			Response	ORR	CR	PR	SD	PD	Response assessment at cycle 8 (sequential treatment), cycle 6 (combination treatment), or at last available response assessment for patients who discontinued treatment before these time points.
Brentuximab Vedotin Sequentially With CHOP or	Combined With CHP in Front-line CD30+ PTCI		Disease diagnoses	<ul> <li>included:</li> <li>32 patients with systemic AI CI</li> </ul>	<ul> <li>ALK-positive, n=6</li> </ul>	<ul> <li>ALK-negative, n=26</li> <li>7 nationts with other</li> </ul>		<ul> <li>PTCL-NOS, n=2</li> <li>AITL, n=2</li> </ul>	<ul> <li>Enteropathy- associated T-rell</li> </ul>	lymphoma, n=1	<ul> <li>Adult I-cell</li> <li>leukemia/lymphoma,</li> <li>n=2</li> </ul>

Fanale MA, et al. J Clin Oncol. 2014;32(28):3137-3143.

## Conclusions

- PTCL are an heterogeneous group of diseases with a very dismal prognosis
- Central pathology review to reference pathology lab is mandatory, as the reproducibility of diagnosis is only 70% in expert hands.
- Prognostic models are only able to predict a poor or a very poor treatment outcome.
- PET imaging + traditional prognostic markers should be assessed in prospective trials.
- CD 30 is highly expressed in several PTCL subsets and anti CD 30 mo Abs proved very active both in relapse and first-line treatment of PTCL

## Thank you for the attention



Pr. Andrea Gallamini Research, Innovation and Statistics. A. Lacassagne Cancer Center, Nice - France

### andreagallamini@gmail.com

